Potential of intermittent hormone therapy for M+ and MO prostate cancer patients

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 4, 2000, Pages 286-289

  Oliver, R T D ^a   Farrugia, D ^a   Ansell, W ^a   Williams, G ^a   Chinegwundoh, F ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Intermittent hormone therapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG INTERMITTENT THERAPY; HORMONE DEPENDENCE; HORMONE RESISTANCE; HUMAN; MALE; METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REMISSION; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034506080     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500483     Document Type: Article

References (26)

1. Combined androgen blockade: Current controversies. Intermittent/early versus late
2. Androgen deprivation therapy for prostate cancer results in significant loss of bone density
3. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade
4. Immediate versus deferred treatment for advanced prostatic cancer; initital results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group
5. Intermittent Endocrine therapy for prostate cancer
6. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience [Review]
7. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
8. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer
9. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCap prostate tumour model
10. Experimental treatment of prostatic cancer by intermittent hormonal therapy
11. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate
12. Human prostate tumour growth in athymic mice: Inhibition by andogens and stimulation by finasteride
13. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer
14. Intermittent androgen deprivation after PSA complete response as a strategy to reduce induction of hormone resistant prostate cancer
15. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
16. Intermittent endocrine therapy for advanced prostate cancer
17. Prospective observational study to asses value of prostate cancer in England and Wales
18. Short-term cellular effects caused by castration therapy in relation to clinical outcome in prostate cancer
19. Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration
20. Hormone release and intermittent hormonal therapy in the LN Cap model of human prostate cancer
21. T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy
22. Synergistic effect of lentinan and surgical endocrine therapy of the growth of DMBA-induced mammary tumours of rats and of recurrent human breast cancer
23. Gonadal atrophy as a cause of thymic hyperplasia after chemotherapy
24. Castration-induced lymphocytosis in prostate cancer: Possible evidence for gonad/thymus endocrine interaction in man
25. Reversibility of prostatic intraepithelial neoplasia: Implications for Chemoprevention
26. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer